RHRakesh Heer

Rakesh Heer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rakesh Heer has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial

    by Diana Johnson, Ruth Thomas, Seonaidh Cotton, Rumana Newlands, David Cooper, Sharon McCann, Luke Vale, Katie Gillies, Axel Bex, Ben Challacombe, et al.

    Background: Localised renal cell carcinoma is treated with radical nephrectomy (RN) or partial nephrectomy (PN). Nephron-sparing PN increases preservation of renal function, reducing incidence of end stage renal failure and associated cardiovascular events. In patients with exophytic T1a (≤ 4 cm) tumours and normal contralateral kidney, PN is standard of care. In patients with T1b (> 4–7 cm) or endophytic T1a tumours and normal contralateral kidney, the benefits of PN over RN are less clear as there are increased surgical complications and more tissue may be excised reducing the preservation of renal function. There are no high-quality studies to address if PN is superior to RN in these more complex cases. Methods: PARTIAL is a pragmatic randomised controlled parallel group unblinded superiority trial with embedded internal pilot and economic and process evaluation. A total of 420 participants will be recruited in UK NHS centres with expertise in minimally invasive nephrectomy techniques. Eligible consenting adults with a single T1 renal cell carcinoma, normal contralateral kidney and equipoise within the multidisciplinary team confirming suitability to receive both interventions by minimally invasive approaches are randomised 1:1 to PN or RN. Patients with metastatic disease, existing chronic kidney disease, solitary functioning kidney, congenital renal abnormality, inherited kidney cancer syndrome, who lack capacity to consent or are pregnant or breast feeding are excluded. Primary outcomes are gains in preservation of renal function at 2 years and surgical complications over the peri-operative period. Secondary outcomes are quality of life and recovery, cost and cost-effectiveness, rates of positive surgical margin, recurrence and cardiovascular events, overall survival, progression to chronic kidney disease and end stage renal failure, operative conversion and patient acceptability. Participants are followed up for 2 years with outcomes collected from medical records and participant questionnaires. Discussion: PARTIAL will determine if gains from PN are superior to RN and offset the potential harms and costs in complex T1 renal tumours suitable for either approach. If PN is not found to provide clinically significant gains and excess complications are confirmed, then a practice-changing case for RN as standard of care could be made. Trial registration: ISRCTN 11293415. Registered prospectively on 19 January 2023.

  • Open Access

    AI-Based Clinical Rule Discovery for NMIBC Recurrence through Tsetlin Machines

    by Saram Abbas, Naeem Soomro, Rishad Shafik, Rakesh Heer, Kabita Adhikari

    Bladder cancer claims one life every 3 minutes worldwide. Most patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC), yet up to 70% recur after treatment, triggering a relentless cycle of surgeries, monitoring, and risk of progression. Clinical tools like the EORTC risk tables are outdated and unreliable - especially for intermediate-risk cases. We propose an interpretable AI model using the Tsetlin Machine (TM), a symbolic learner that outputs transparent, human-readable logic. Tested on the PHOTO trial dataset (n=330), TM achieved an F1-score of 0.80, outperforming XGBoost (0.78), Logistic Regression (0.60), and EORTC (0.42). TM reveals the exact clauses behind each prediction, grounded in clinical features like tumour count, surgeon experience, and hospital stay - offering accuracy and full transparency. This makes TM a powerful, trustworthy decision-support tool ready for real-world adoption.


  • Open Access

    Attention-enabled Explainable AI for Bladder Cancer Recurrence Prediction

    by Saram Abbas, Naeem Soomro, Rishad Shafik, Rakesh Heer, Kabita Adhikari

    Non-muscle-invasive bladder cancer (NMIBC) is a relentless challenge in oncology, with recurrence rates soaring as high as 70-80%. Each recurrence triggers a cascade of invasive procedures, lifelong surveillance, and escalating healthcare costs - affecting 460,000 individuals worldwide. However, existing clinical prediction tools remain fundamentally flawed, often overestimating recurrence risk and failing to provide personalized insights for patient management. In this work, we propose an interpretable deep learning framework that integrates vector embeddings and attention mechanisms to improve NMIBC recurrence prediction performance. We incorporate vector embeddings for categorical variables such as smoking status and intravesical treatments, allowing the model to capture complex relationships between patient attributes and recurrence risk. These embeddings provide a richer representation of the data, enabling improved feature interactions and enhancing prediction performance. Our approach not only enhances performance but also provides clinicians with patient-specific insights by highlighting the most influential features contributing to recurrence risk for each patient. Our model achieves accuracy of 70% with tabular data, outperforming conventional statistical methods while providing clinician-friendly patient-level explanations through feature attention. Unlike previous studies, our approach identifies new important factors influencing recurrence, such as surgical duration and hospital stay, which had not been considered in existing NMIBC prediction models.


  • Open Access

    Using artificial intelligence for bladder cancer detection during cystoscopy and its impact on clinical outcomes: a protocol for a systematic review and meta-analysis

    by Mohamed Baana, Murtada Arkwazi, Yi Zhao, Ojone Ofagbor, Gaurika Bhardwaj, Mariam Lami, Eva Bolton, Rakesh Heer

    Introduction Cystoscopy has revolutionised the process of diagnosing bladder cancer leading to better categorisation of risk levels and more precise treatment plans. Nonetheless, concerns arise about the lack of uniformity among observers in predicting tumour stage and grade. To address these concerns, artificial intelligence (AI) is being incorporated into clinical settings to aid in the analysis of diagnostic and therapeutic images. The subsequent report outlines a systematic review and meta-analysis protocol aimed at evaluating the effectiveness of AI in predicting bladder cancer based on cystoscopic images. Methods and analysis Our systematic search will use databases including PubMed, MEDLINE, Embase and Cochrane. The articles published between May 2015 and April 2024 will be eligible for inclusion. For articles to be considered, they must employ AI for analysis of cystoscopic images to identify bladder cancer, present original data and be written in English. The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol 2015 checklist. Quality and bias risk across chosen studies will be evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 score. Ethics and dissemination Ethical clearance will not be necessary for conducting this systematic review since results will be disseminated through peer-reviewed publications and presentations at both national and international conferences. PROSPERO registration number CRD42024528345.


  • Open Access

    The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer

    by Beth Adamson, Nicholas Brittain, Laura Walker, Ruaridh Duncan, Sara Luzzi, Pasquale Rescigno, Graham Smith, Suzanne McGill, Richard J.S. Burchmore, Elaine Willmore, et al.

    Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy of treatments. In contrast to full-length AR (AR-FL), AR-Vs constitutively activate androgenic signaling and are refractory to the current repertoire of AR-targeting therapies, which together drive disease progression. There is an unmet clinical need, therefore, to develop more durable PC therapies that can attenuate AR-V function. Exploiting the requirement of coregulatory proteins for AR-V function has the capacity to furnish tractable routes for attenuating persistent oncogenic AR signaling in advanced PC. DNA-PKcs regulates AR-FL transcriptional activity and is upregulated in both early and advanced PC. We hypothesized that DNA-PKcs is critical for AR-V function. Using a proximity biotinylation approach, we demonstrated that the DNA-PK holoenzyme is part of the AR-V7 interactome and is a key regulator of AR-V–mediated transcription and cell growth in models of advanced PC. Crucially, we provide evidence that DNA-PKcs controls global splicing and, via RBMX, regulates the maturation of AR-V and AR-FL transcripts. Ultimately, our data indicate that targeting DNA-PKcs attenuates AR-V signaling and provide evidence that DNA-PKcs blockade is an effective therapeutic option in advanced AR-V–positive patients with PC.